Clinical trial · Observational
Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis. Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation) but they suffer from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time. A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Psoriasis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Psoriasis
- description
- Patients with psoriasis
- interventionNames
- Other: Blood samples
Primary outcomes (1)
- measure
- SCCA blood concentration
- timeFrame
- Baseline, 3 months and 6 months
- description
- SCCA blood concentration will be measured at each visit
Secondary outcomes (5)
- measure
- Assess correlations between SCCA blood concentration and proSPI severity score
- timeFrame
- Baseline, 3 months and 6 months
- description
- proSPI severity score (0-50) will be evaluated at each visit
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old * Patient with skin psoriasis (new and untreated or being treated, flare-up or stable, possibly bleached) * Requiring a blood sample for disease or treatment monitoring Exclusion Criteria: * History of invasive mucosal squamous cell carcinoma, or squamous cell carcinoma of the skin with lymph node or visceral recurrence. * Patient under guardianship or curatorship * Opposition to participation in the study
References
Publications (0)
Data not yet available